marketcaparena
Search

    ACRS

    Aclaris Therapeutics, Inc.

    Company overview

    Market capitalization
    $799.29M
    Employees
    69
    Latest publication
    2026-09-29
    About Aclaris Therapeutics, Inc.

    Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ1 20252025-03-31 · USDQ4 20172017-12-31 · USDQ3 20172017-09-30 · USDQ2 20172017-06-30 · USDQ1 20172017-03-31 · USD
    Total Revenue1,996,000USD1,295,000USD3,299,000USD1,455,000USD999,000USD684,000USD0USD0USD
    Cost Of Revenue395,000USD-803,000USD538,000USD506,000USD754,000USD453,000USD15,040,000USD12,880,000USD
    Gross Profit1,601,000USD2,098,000USD2,761,000USD949,000USD245,000USD231,000USD0USD0USD
    Research Development15,657,000USD16,584,000USD13,028,000USD11,584,000USD13,189,000USD10,864,000USD7,965,000USD7,772,000USD
    Selling General Administrative6,743,000USD5,576,000USD4,871,000USD6,139,000USD5,406,000USD4,566,000USD4,142,000USD3,720,000USD
    Unclassified Operating Expenses1,393,000USD2,672,000USD2,011,000USD1,310,000USD————
    Total Operating Expenses23,793,000USD24,832,000USD19,910,000USD19,033,000USD25,687,000USD18,987,000USD15,295,000USD12,930,000USD
    Operating Income-22,192,000USD-22,734,000USD-17,149,000USD-18,084,000USD-25,442,000USD-18,756,000USD-15,295,000USD-12,930,000USD
    Interest Income1,514,000USD1,634,000USD1,819,000USD2,166,000USD————
    Net Interest Income1,514,000USD1,634,000USD1,819,000USD2,166,000USD————
    Income Before Tax-19,824,000USD-19,795,000USD-14,614,000USD-15,085,000USD-24,764,000USD-18,192,000USD-14,838,000USD-12,559,000USD
    Net Income-19,824,000USD-19,795,000USD-14,614,000USD-15,085,000USD-22,934,000USD-18,192,000USD-14,838,000USD-12,559,000USD
    Net Income From Continuing Ops-19,824,000USD-19,795,000USD-14,614,000USD-15,085,000USD-34,329,000USD-18,192,000USD-14,838,000USD-12,559,000USD
    Ebit-19,824,000USD-19,795,000USD-14,614,000USD-17,784,000USD-25,166,000USD-18,756,000USD-14,838,000USD-12,930,000USD
    Ebitda-19,722,000USD-19,693,000USD-14,404,000USD-17,656,000USD-24,985,000USD-18,640,000USD-14,783,000USD-12,880,000USD
    Depreciation And Amortization102,000USD102,000USD210,000USD128,000USD181,000USD116,000USD55,000USD50,000USD
    Reconciled Depreciation102,000USD102,000USD110,000USD128,000USD181,000USD116,000USD55,000USD50,000USD
    Total Other Income Expense Net2,368,000USD2,939,000USD2,535,000USD2,999,000USD678,000USD564,000USD457,000USD371,000USD
    Selling And Marketing Expenses————6,586,000USD3,557,000USD2,188,000USD1,438,000USD
    Interest Expense————0USD0USD0USD0USD
    Income Tax Expense————-1,830,000USD0USD0USD0USD
    Minority Interest————0USD0USD0USD0USD
    Discontinued Operations————0USD0USD0USD0USD
    Net Income Applicable To Common Shares————-34,329,000USD-18,192,000USD-14,838,000USD-12,559,000USD
    Non Operating Income Net Other—————564,000USD457,000USD371,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20152015-12-31 · USDFY 20142014-12-31 · USDFY 20132013-12-31 · USD
    Total Revenue0USD0USD—
    Cost Of Revenue90,000USD0USD—
    Gross Profit-90,000USD0USD—
    Research Development15,339,000USD6,507,000USD3,488,000USD
    Selling General Administrative5,328,000USD2,026,000USD1,769,000USD
    Total Operating Expenses20,667,000USD8,533,000USD5,257,000USD
    Operating Income-20,667,000USD-8,533,000USD-5,257,000USD
    Interest Income104,000USD——
    Interest Expense0USD0USD0USD
    Income Before Tax-20,563,000USD-8,517,000USD-5,236,000USD
    Income Tax Expense-90,000USD0USD—
    Net Income-20,563,000USD-8,517,000USD-5,236,000USD
    Net Income From Continuing Ops-20,563,000USD-8,517,000USD—
    Ebit-20,667,000USD-8,533,000USD-5,257,000USD
    Ebitda-20,577,000USD-8,521,000USD-5,246,000USD
    Depreciation And Amortization90,000USD12,000USD11,000USD
    Total Other Income Expense Net104,000USD16,000USD21,000USD
    Non Operating Income Net Other104,000USD——
    Net Income Applicable To Common Shares-23,129,000USD-10,571,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Assets198,720,000USD160,460,000USD175,534,000USD189,147,000USD198,094,000USD220,327,000USD182,394,000USD161,071,000USD
    Other Current Assets4,814,000USD55,047,000USD4,680,000USD4,202,000USD3,226,000USD12,039,000USD4,265,000USD6,217,000USD
    Total Liab55,071,000USD57,378,000USD55,434,000USD57,408,000USD54,028,000USD64,773,000USD52,243,000USD27,249,000USD
    Total Stockholder Equity143,649,000USD103,082,000USD120,100,000USD131,739,000USD144,066,000USD155,554,000USD130,151,000USD133,822,000USD
    Other Current Liab8,097,999USD10,993,000USD9,614,000USD8,197,000USD14,662,000USD23,016,000USD6,924,000USD7,964,000USD
    Common Stock1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD
    Capital Stock1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD
    Retained Earnings-987,608,000USD-967,784,000USD-947,989,000USD-933,375,000USD-917,946,000USD-902,861,000USD-806,309,000USD-798,723,000USD
    Cash28,660,000USD19,960,000USD25,256,000USD25,402,000USD30,357,000USD24,570,000USD47,651,000USD22,834,000USD
    Cash And Short Term Investments105,416,000USD90,751,000USD95,912,000USD99,806,000USD105,314,000USD113,594,000USD127,722,000USD111,093,000USD
    Total Current Assets110,230,000USD151,363,000USD100,592,000USD104,202,000USD108,790,000USD125,951,000USD132,330,000USD117,635,000USD
    Total Current Liabilities27,370,000USD28,645,000USD25,631,000USD26,839,000USD21,514,000USD31,596,000USD18,816,000USD15,682,000USD
    Current Deferred Revenue3,972,000USD3,943,000USD6,297,000USD9,330,000USD3,888,000USD3,890,000USD3,765,000USD—
    Net Debt-26,675,000USD-17,844,000USD-23,012,000USD-23,036,000USD-27,873,000USD-24,570,000USD-44,941,000USD-20,018,000USD
    Short Term Debt569,000USD551,000USD533,000USD515,000USD498,000USD481,000USD465,000USD449,000USD
    Short Long Term Debt Total1,985,000USD2,116,000USD2,244,000USD2,366,000USD2,484,000USD2,598,000USD2,710,000USD2,816,000USD
    Long Term Investments85,372,000USD60,612,000USD71,297,000USD81,084,000USD85,211,000USD90,302,000USD45,714,000USD38,778,000USD
    Short Term Investments76,756,000USD70,791,000USD70,656,000USD74,404,000USD74,957,000USD89,024,000USD80,071,000USD88,259,000USD
    Net Receivables4,814,000USD5,565,000USD4,680,000USD194,000USD250,000USD318,000USD343,000USD325,000USD
    Accounts Payable14,731,000USD13,158,000USD9,187,000USD8,797,000USD6,354,000USD4,690,000USD7,662,000USD7,269,000USD
    Property Plant Equipment Net2,887,000USD761,000USD3,239,000USD868,000USD942,000USD1,008,000USD1,133,000USD1,293,000USD
    Accumulated Other Comprehensive Income22,000USD610,000USD597,000USD482,000USD434,000USD97,000USD427,000USD-463,000USD
    Common Stock Shares Outstanding128,810,050shares122,664,768shares122,619,311shares122,580,967shares122,390,303shares95,305,768shares71,381,731shares71,291,400shares
    Non Current Assets Total88,490,000USD9,097,000USD74,942,000USD84,945,000USD89,304,000USD94,376,000USD50,064,000USD43,436,000USD
    Non Current Liabilities Total27,700,999USD28,733,000USD29,803,000USD30,569,000USD32,514,000USD33,177,000USD33,427,000USD11,567,000USD
    Non Current Liabilities Other12,416,000USD12,565,000USD12,311,000USD12,351,000USD13,308,000USD13,139,000USD12,245,000USD11,567,000USD
    Non Currrent Assets Other231,000USD-51,515,000USD406,000USD2,993,000USD3,151,000USD3,066,000USD3,217,000USD3,365,000USD
    Net Working Capital82,860,000USD67,671,000USD74,961,000USD77,363,000USD87,276,000USD94,355,000USD113,514,000USD101,953,000USD
    Unclassified Current Assets-4,814,000USD—-4,680,000USD—————
    Unclassified Non Current Liabilities15,284,999USD16,168,000USD17,492,000USD18,218,000USD19,206,000USD20,038,000USD21,182,000USD—
    Unclassified Equity1,131,233,000USD1,070,254,000USD1,067,490,000USD1,064,630,000USD1,061,576,000USD1,058,316,000USD936,031,000USD933,006,000USD
    Unclassified Non Current Assets—-52,276,000USD——————
    Property Plant Equipment Gross——5,795,000USD5,878,000USD5,856,000USD5,813,000USD5,813,000USD5,813,000USD
    Unclassified Current Liabilities————-3,888,000USD———
    Other Assets———————1USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets160,460,000USD220,327,000USD197,405,000USD254,596,000USD251,211,000USD70,784,000USD98,297,000USD275,566,000USD
    Other Current Assets55,047,000USD12,039,000USD9,452,000USD13,495,000USD12,995,000USD2,590,000USD3,118,000USD10,173,000USD
    Total Liab57,378,000USD64,773,000USD40,226,000USD56,975,000USD53,870,000USD33,134,000USD28,385,000USD60,442,000USD
    Total Stockholder Equity103,082,000USD155,554,000USD157,179,000USD197,621,000USD197,341,000USD37,650,000USD69,912,000USD215,124,000USD
    Other Current Liab10,993,000USD23,016,000USD2,202,000USD10,903,000USD12,253,000USD9,017,000USD4,157,000USD15,525,000USD
    Common Stock1,000USD1,000USD1,000USD1,000USD1,000USD———
    Capital Stock1,000USD1,000USD1,000USD1,000USD1,000USD0USD0USD0USD
    Retained Earnings-967,784,000USD-902,861,000USD-770,796,000USD-682,315,000USD-595,407,000USD-504,542,000USD-453,527,000USD-292,173,000USD
    Cash19,960,000USD24,570,000USD39,878,000USD45,277,000USD27,349,000USD22,063,000USD35,937,000USD57,019,000USD
    Cash And Short Term Investments90,751,000USD113,594,000USD119,106,000USD217,571,000USD191,414,000USD54,131,000USD75,015,000USD167,972,000USD
    Total Current Assets151,363,000USD125,951,000USD128,856,000USD231,550,000USD205,032,000USD57,493,000USD83,803,000USD179,499,000USD
    Total Current Liabilities28,645,000USD31,596,000USD30,952,000USD21,938,000USD22,931,000USD14,874,000USD22,432,000USD27,342,000USD
    Current Deferred Revenue3,943,000USD3,890,000USD19,446,000USD—10,051,000USD5,906,000USD7,721,000USD—
    Net Debt-17,844,000USD-24,570,000USD-39,452,000USD-44,593,000USD-26,656,000USD-10,807,000USD-35,300,000USD-26,504,000USD
    Short Term Debt551,000USD962,000USD426,000USD684,000USD693,000USD603,000USD637,000USD142,000USD
    Short Long Term Debt Total2,116,000USD2,598,000USD426,000USD684,000USD693,000USD11,256,000USD658,000USD30,515,000USD
    Long Term Investments60,612,000USD90,302,000USD62,771,000USD12,242,000USD34,242,000USD0USD—0USD
    Short Term Investments70,791,000USD89,024,000USD79,228,000USD172,294,000USD164,065,000USD32,068,000USD39,078,000USD110,953,000USD
    Net Receivables5,565,000USD318,000USD298,000USD484,000USD623,000USD772,000USD704,000USD563,000USD
    Accounts Payable13,158,000USD4,690,000USD8,878,000USD10,351,000USD9,985,000USD5,254,000USD9,917,000USD11,675,000USD
    Property Plant Equipment Net761,000USD1,008,000USD1,620,000USD1,099,000USD1,335,000USD1,654,000USD2,470,000USD4,280,000USD
    Accumulated Other Comprehensive Income610,000USD97,000USD-106,000USD-897,000USD-224,000USD-94,000USD-66,000USD-69,000USD
    Common Stock Shares Outstanding122,664,768shares77,296,665shares69,808,855shares65,213,944shares56,730,583shares42,539,293shares41,323,921shares32,909,762shares
    Non Current Assets Total9,097,000USD94,376,000USD68,549,000USD23,046,000USD46,179,000USD13,291,000USD14,494,000USD96,067,000USD
    Non Current Liabilities Total28,733,000USD33,177,000USD9,274,000USD35,037,000USD30,939,000USD18,260,000USD5,953,000USD33,100,000USD
    Non Current Liabilities Other12,565,000USD13,139,000USD9,274,000USD34,670,000USD30,572,000USD7,240,000USD5,404,000USD2,637,000USD
    Non Currrent Assets Other-51,515,000USD3,066,000USD1,743,000USD2,732,000USD3,554,000USD4,514,000USD4,825,000USD332,000USD
    Net Working Capital67,671,000USD94,355,000USD97,904,000USD209,612,000USD182,101,000USD42,619,000USD61,371,000USD152,157,000USD
    Unclassified Non Current Assets-52,276,000USD—2,146,000USD-1,737,000USD-251,211,000USD-4,514,000USD—-68,002,000USD
    Unclassified Non Current Liabilities16,168,000USD20,038,000USD—-33,467,000USD-28,767,000USD-7,607,000USD-2,384,000USD-3,186,000USD
    Unclassified Equity1,070,254,000USD1,058,316,000USD928,079,000USD880,831,000USD792,970,000USD542,286,000USD523,505,000USD507,366,000USD
    Property Plant Equipment Gross—5,813,000USD5,782,000USD5,134,000USD4,728,000USD1,654,000USD2,470,000USD4,280,000USD
    Intangible Assets——269,000USD6,973,000USD7,048,000USD7,123,000USD7,199,000USD72,951,000USD
    Deferred Long Term Liab———367,000USD367,000USD367,000USD549,000USD549,000USD
    Other Liab———33,467,000USD28,767,000USD7,607,000USD2,384,000USD3,186,000USD
    Other Assets———1,737,000USD251,211,000USD4,514,000USD92,000USD68,002,000USD
    Inventory———-12,242,000USD-34,242,000USD—4,966,000USD791,000USD
    Net Tangible Assets———190,648,000USD190,293,000USD30,527,000USD62,713,000USD189,346,000USD
    Unclassified Current Liabilities————-10,051,000USD-5,906,000USD——
    Long Term Debt—————10,653,000USD—29,914,000USD
    Good Will——————0USD18,504,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-19,824,000USD-19,795,000USD-14,614,000USD-15,429,000USD-15,085,000USD-96,552,000USD-7,586,000USD-10,986,000USD
    Depreciation102,000USD102,000USD210,000USD114,000USD128,000USD143,000USD200,000USD242,000USD
    Stock Based Compensation3,198,000USD2,926,000USD2,860,000USD3,063,000USD3,535,000USD2,860,000USD3,004,000USD2,903,000USD
    Other Non Cash Items3,198,000USD400,000USD2,860,000USD1,500,000USD300,000USD85,605,000USD3,783,000USD200,000USD
    Change To Account Receivables742,000USD-672,000USD6,686,000USD-8,152,000USD8,276,000USD25,000USD-18,000USD48,000USD
    Change In Working Capital-1,625,000USD3,236,000USD612,000USD759,000USD-1,935,000USD-994,000USD25,603,000USD-4,681,000USD
    Total Cash From Operating Activities-18,149,000USD-13,131,000USD-10,932,000USD-9,993,000USD-13,057,000USD-8,938,000USD22,000,000USD-12,322,000USD
    Capital Expenditures-13,000USD-24,000USD-23,000USD-21,000USD-876,000USD-35,810,000USD0USD-14,000USD
    Free Cash Flow-18,149,000USD-13,155,000USD-10,955,000USD-10,014,000USD-13,933,000USD-44,748,000USD22,000,000USD-12,308,000USD
    Investments-30,919,000USD10,393,000USD13,830,000USD5,047,000USD19,119,000USD-88,723,000USD2,795,000USD-674,000USD
    Total Cashflows From Investing Activities-30,932,000USD10,369,000USD13,830,000USD5,047,000USD19,119,000USD-88,723,000USD2,795,000USD-674,000USD
    Total Cash From Financing Activities57,781,000USD-2,534,000USD-3,044,000USD-9,000USD-275,000USD74,580,000USD22,000USD-11,000USD
    Issuance Of Capital Stock57,880,000USD———0USD74,913,000USD0USD—
    Change In Cash8,700,000USD-5,296,000USD-146,000USD-4,955,000USD5,787,000USD-23,081,000USD24,817,000USD-13,007,000USD
    Begin Period Cash Flow19,960,000USD25,256,000USD25,402,000USD30,357,000USD24,570,000USD47,651,000USD22,834,000USD35,841,000USD
    End Period Cash Flow28,660,000USD19,960,000USD25,256,000USD25,402,000USD30,357,000USD24,570,000USD47,651,000USD22,834,000USD
    Other Cashflows From Financing Activities-250,000USD-2,372,000USD-3,044,000USD-9,000USD-275,000USD-333,000USD-10,000USD-11,000USD
    Unclassified Operating Cash Flow-3,198,000USD—-2,860,000USD———-3,004,000USD—
    Sale Purchase Of Stock—-162,000USD275,000USD-9,000USD-275,000USD-333,000USD-10,000USD-11,000USD
    Other Cashflows From Investing Activities—29,246,000USD——-833,000USD-35,810,000USD—-688,000USD
    Unclassified Investing Cash Flow—-29,246,000USD——1,709,000USD71,620,000USD——
    Unclassified Financing Cash Flow—————75,246,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-64,923,000USD-132,065,000USD-88,481,000USD-86,908,000USD-90,865,000USD-51,015,000USD-113,542,000USD-132,738,000USD
    Depreciation454,000USD807,000USD863,000USD797,000USD923,000USD1,324,000USD1,586,000USD1,879,000USD
    Stock Based Compensation12,384,000USD10,856,000USD20,542,000USD15,039,000USD14,060,000USD11,207,000USD16,177,000USD20,055,000USD
    Other Non Cash Items2,300,000USD89,405,000USD-20,271,000USD4,700,000USD24,339,000USD2,393,000USD18,214,000USD555,000USD
    Change To Account Receivables6,138,000USD-20,000USD186,000USD139,000USD149,000USD4,898,000USD-809,000USD-4,380,000USD
    Change In Working Capital2,672,000USD10,922,000USD9,389,000USD-1,195,000USD-1,343,000USD-2,360,000USD-2,703,000USD9,438,000USD
    Total Cash From Operating Activities-47,113,000USD-20,075,000USD-78,325,000USD-67,567,000USD-52,134,000USD-38,633,000USD-96,445,000USD-100,811,000USD
    Capital Expenditures-111,000USD-121,000USD-1,309,000USD-605,000USD-308,000USD-453,000USD-1,613,000USD-1,356,000USD
    Free Cash Flow-47,113,000USD-20,196,000USD-79,634,000USD-68,172,000USD-52,442,000USD-39,086,000USD-98,058,000USD-102,167,000USD
    Investments49,309,000USD-69,769,000USD46,220,000USD12,628,000USD-167,324,000USD6,840,000USD73,106,000USD77,845,000USD
    Total Cashflows From Investing Activities48,365,000USD-69,769,000USD46,220,000USD12,628,000USD-167,632,000USD6,387,000USD105,679,000USD9,367,000USD
    Total Cash From Financing Activities-5,862,000USD74,536,000USD26,706,000USD72,867,000USD225,052,000USD18,372,000USD-30,316,000USD128,261,000USD
    Sale Purchase Of Stock-446,000USD—-102,000USD-34,000USD-3,124,000USD7,737,000USD207,000USD100,782,000USD
    Issuance Of Capital Stock0USD74,913,000USD26,714,000USD72,744,000USD238,200,000USD7,737,000USD25,000USD100,205,000USD
    Change In Cash-4,610,000USD-15,308,000USD-5,399,000USD17,928,000USD5,286,000USD-13,874,000USD-21,082,000USD36,817,000USD
    Begin Period Cash Flow24,570,000USD39,878,000USD45,277,000USD27,349,000USD22,063,000USD35,937,000USD57,019,000USD20,202,000USD
    End Period Cash Flow19,960,000USD24,570,000USD39,878,000USD45,277,000USD27,349,000USD22,063,000USD35,937,000USD57,019,000USD
    Other Cashflows From Investing Activities-833,000USD-35,810,000USD—13,233,000USD-167,324,000USD6,840,000USD34,186,000USD77,845,000USD
    Other Cashflows From Financing Activities-5,416,000USD-377,000USD-8,000USD123,000USD-1,665,000USD10,772,000USD207,000USD-1,206,000USD
    Unclassified Investing Cash Flow—35,931,000USD1,309,000USD-12,628,000USD167,324,000USD-6,840,000USD—-144,967,000USD
    Net Borrowings——0USD0USD-11,483,000USD10,913,000USD-30,000,000USD29,262,000USD
    Unclassified Financing Cash Flow——26,816,000USD72,778,000USD244,448,000USD-3,313,000USD——
    Change To Liabilities———960,000USD4,125,000USD-8,947,000USD-5,127,000USD13,756,000USD
    Cash And Cash Equivalents Changes———17,928,000USD5,286,000USD-13,874,000USD-21,082,000USD36,817,000USD
    Dividends Paid————-3,124,000USD-7,737,000USD——
    Change To Inventory——————605,000USD102,000USD
    Unclassified Operating Cash Flow——————-16,177,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductLaboratory Research Revenue537,000USD0001104659-26-057202
    Q1 2026Quarterly · 2026-03-31ProductLicense And Service1,459,000USD0001104659-26-057202
    Q4 2025Quarterly · 2025-12-31ProductLaboratory Research Revenue500,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductLicense And Service795,000USDLegacy provider
    FY 2025Yearly · 2025-12-31ProductLaboratory Research Revenue1,872,000USD0001104659-26-020540
    FY 2025Yearly · 2025-12-31ProductLicense And Service5,954,000USD0001104659-26-020540
    Q3 2025Quarterly · 2025-09-30ProductLaboratory Research Revenue485,000USD0001104659-25-107788
    Q3 2025Quarterly · 2025-09-30ProductLicense And Service2,814,000USD0001104659-25-107788
    Q2 2025Quarterly · 2025-06-30ProductLaboratory Research Revenue442,000USD0001558370-25-010789
    Q2 2025Quarterly · 2025-06-30ProductLicense And Service1,335,000USD0001558370-25-010789
    Q1 2025Quarterly · 2025-03-31ProductLaboratory Research Revenue445,000USD0001104659-26-057202
    Q1 2025Quarterly · 2025-03-31ProductLicense And Service1,010,000USD0001104659-26-057202
    Q4 2024Quarterly · 2024-12-31ProductLaboratory Research Revenue614,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductLicense And Service8,596,000USDLegacy provider
    FY 2024Yearly · 2024-12-31ProductLaboratory Research Revenue2,541,000USD0001104659-26-020540
    FY 2024Yearly · 2024-12-31ProductLicense And Service16,179,000USD0001104659-26-020540
    Q3 2024Quarterly · 2024-09-30ProductLaboratory Research Revenue645,000USD0001104659-25-107788
    Q3 2024Quarterly · 2024-09-30ProductLicense And Service3,701,000USD0001104659-25-107788
    Q3 2024Quarterly · 2024-09-30SegmentContract Research645,000USD0001558370-24-014646
    Q3 2024Quarterly · 2024-09-30SegmentDermatology Therapeutics3,701,000USD0001558370-24-014646
    Q2 2024Quarterly · 2024-06-30ProductLaboratory Research Revenue625,000USD0001558370-25-010789
    Q2 2024Quarterly · 2024-06-30ProductLicense And Service2,141,000USD0001558370-25-010789
    Q2 2024Quarterly · 2024-06-30SegmentContract Research625,000USD0001558370-24-011376
    Q2 2024Quarterly · 2024-06-30SegmentDermatology Therapeutics2,141,000USD0001558370-24-011376
    Q1 2024Quarterly · 2024-03-31SegmentContract Research657,000USD0001558370-24-007069
    Q1 2024Quarterly · 2024-03-31SegmentDermatology Therapeutics1,741,000USD0001558370-24-007069
    FY 2023Yearly · 2023-12-31ProductLaboratory Research Revenue3,035,000USD0001558370-25-001819
    FY 2023Yearly · 2023-12-31ProductLicense And Service28,214,000USD0001558370-25-001819
    Q4 2023Quarterly · 2023-12-31SegmentContract Research564,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31SegmentDermatology Therapeutics17,006,000USDLegacy provider
    FY 2023Yearly · 2023-12-31SegmentContract Research3,035,000USD0001558370-24-001753
    FY 2023Yearly · 2023-12-31SegmentDermatology Therapeutics28,214,000USD0001558370-24-001753
    Q3 2023Quarterly · 2023-09-30SegmentContract Research705,000USD0001558370-24-014646
    Q3 2023Quarterly · 2023-09-30SegmentDermatology Therapeutics8,577,000USD0001558370-24-014646
    Q2 2023Quarterly · 2023-06-30SegmentContract Research876,000USD0001558370-24-011376
    Q2 2023Quarterly · 2023-06-30SegmentDermatology Therapeutics993,000USD0001558370-24-011376
    Q1 2023Quarterly · 2023-03-31SegmentContract Research890,000USD0001558370-24-007069
    Q1 2023Quarterly · 2023-03-31SegmentDermatology Therapeutics1,638,000USD0001558370-24-007069
    FY 2022Yearly · 2022-12-31ProductLaboratory Research Revenue4,395,000USD0001558370-24-001753
    FY 2022Yearly · 2022-12-31ProductLicense And Service25,100,000USD0001558370-24-001753
    FY 2022Yearly · 2022-12-31ProductOther Revenue257,000USD0001558370-24-001753
    FY 2022Yearly · 2022-12-31SegmentContract Research4,396,000USD0001558370-24-001753
    FY 2022Yearly · 2022-12-31SegmentDermatology Therapeutics25,356,000USD0001558370-24-001753
    FY 2021Yearly · 2021-12-31ProductLaboratory Research Revenue5,830,000USD0001558370-24-001753
    FY 2021Yearly · 2021-12-31ProductLicense And Service809,000USD0001558370-24-001753
    FY 2021Yearly · 2021-12-31ProductOther Revenue122,000USD0001558370-24-001753
    FY 2021Yearly · 2021-12-31SegmentContract Research5,829,000USD0001558370-24-001753
    FY 2021Yearly · 2021-12-31SegmentDermatology Therapeutics932,000USD0001558370-24-001753
    FY 2019Yearly · 2019-12-31ProductLaboratory Research Revenue4,227,000USD0001558370-21-001717
    FY 2019Yearly · 2019-12-31ProductRoyalty0USD0001558370-21-001717
    FY 2018Yearly · 2018-12-31ProductLaboratory Research Revenue4,651,000USD0001558370-21-001717
    FY 2018Yearly · 2018-12-31ProductOther Revenue1,500,000USD0001558370-21-001717

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.